Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer

The loss-of-function mutation of formyl peptide receptor 1 (FPR1) has a negative impact on the progression-free and overall survival of breast cancer patients treated with anthracycline-based adjuvant chemotherapy. This effect may be attributed to the fact that chemotherapy-induced antitumor immunit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Baracco, Elisa E., Pietrocola, Federico, Buqué, Aitziber, Bloy, Norma, Senovilla, Laura, Zitvogel, Laurence, Vacchelli, Erika, Kroemer, Guido
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2016
Matèries:
Brief Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4938360/
https://ncbi.nlm.nih.gov/pubmed/27471610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1139275
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars